REV-ERBα activation is shown to ameliorate ulcerative colitis 25,32,33, fulminant hepatitis 27, neuroinflammation 34,35, heart failure 36,37, myocardial infarction 38, experimental autoimmune encephalomyelitis 33,39, and pulmonary inflammation 29,40. Here, NR1D1 is linked to ulcerative colitis.